Berenberg Bank set a €116.00 ($136.47) target price on Merck KGaA (FRA:MRK) in a research report report published on Thursday. The brokerage currently has a buy rating on the healthcare company’s stock.

Other research analysts have also issued reports about the stock. Kepler Capital Markets set a €119.00 ($140.00) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Monday, July 31st. S&P Global set a €110.00 ($129.41) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, August 3rd. equinet AG set a €112.00 ($131.76) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, August 31st. BNP Paribas set a €116.00 ($136.47) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, September 6th. Finally, Warburg Research set a €115.00 ($135.29) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, September 6th. Eleven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of €108.76 ($127.96).

Merck KGaA (MRK) traded down €0.63 ($0.74) during trading on Thursday, reaching €89.17 ($104.91). 399,695 shares of the company’s stock were exchanged. Merck KGaA has a 52-week low of €89.21 ($104.95) and a 52-week high of €115.00 ($135.29).

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/merck-kgaa-mrk-given-a-116-00-price-target-at-berenberg-bank/1724112.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.